Acquired Thrombotic Thrombocytopenic Purpura Clinical Trial
Official title:
Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura (aTTP)- REACT-2020
The objective of this national, prospective, multi-centre observational study is to describe the prescription rational and practice in Germany, confirm the efficacy of caplacizumab in a real-world setting, and identify predicting factors in iTTP-patients with regard to persistent autoimmune activity, therapy guidance and risk of complications. The rational is to develop new treatment algorithms that optimize overall patient outcome and reduce treatment cost.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02878603 -
Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
|
Phase 3 | |
| Recruiting |
NCT05876221 -
Platelet Response to Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura
|
||
| Recruiting |
NCT05046717 -
Improvement of Immunologic and Molecular Techniques for the Diagnosis and Follow-up of Patients With Thrombotic Thrombocytopenic Purpura
|
||
| Completed |
NCT02553317 -
Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic Purpura
|
Phase 3 | |
| Not yet recruiting |
NCT04021173 -
A Clinical Study of Anfibatide in Acquired Thrombotic Thrombocytopenic Purpura (TTP)
|
Phase 2 | |
| Completed |
NCT01151423 -
Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
|
Phase 2 |